EirGen Pharma Oncology Product Eir-050 Receives Pan-EU Approval
EirGen Pharma are pleased to announce that the company has received approval for its breast cancer Molecule Eir-050 in 25 EU countries on March 11th. The company believe that they are the first company to receive approval for this molecule in the EU. According to co-founder, Tom Brennan, we are delighted to have reached this significant milestone on the same day that the Irish Government published the Innovation Ireland taskforce report in which EirGen were highlighted as a company already operating in an innovative way in performing high level, value adding R&D in Ireland.